Can a new drug help sepsis patients with weak immune systems?

NCT ID NCT07578558

Not yet recruiting Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether adding the drug nogapendekin alfa inbakicept (NAI) to standard sepsis care can improve survival in critically ill adults with sepsis and persistently low lymphocyte counts (a sign of immune suppression). About 50 participants will be randomly assigned to receive either NAI injections plus standard care or standard care alone. The main goal is to see if NAI reduces deaths within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nogapendekin alfa inbakicept (NAI, also known as N-803 or ANKTIVA)
What this could lead to: If successful, this could point toward a new treatment to boost the immune system in sepsis patients, potentially reducing deaths and complications.
What could go wrong: This is a small, early Phase 2 trial with only 50 participants, so results may not apply to all sepsis patients. The drug may not improve survival or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness infectious disease with sepsis lymphopenia Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRITICAL ILLNESS IMMUNOSUPPRESSION LYMPHOPENIA SEPSIS SEPTIC SHOCK

More trials for these conditions

Other studies related to the condition(s) this trial covers.